NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/07/2024
Voltar para busca
Dado oficial do USPTO
EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN.
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN.
ST13
US500000090459471Classe
42
Pedido
90459471
Registro
7443900
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
09/07/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
11/01/2021
Data de registro
09/07/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/07/2024
Última transação
09/07/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2020-08-00
Primeiro uso no comércio
2020-08-00
Código do desenho
4
Tipo de titular
03
Localização do titular
Seattle, WA, US
Examinador
MICHELI, ANGELA M
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Adaptive Biotechnologies Corp.
Representantes
Hoang-chi Truong Patent Law Works LLP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual diseasethe analysisevaluationreporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expressioncancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; researchdevelopmentengineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnologypharmaceutical research and development and genetic science; consulting services in the fields of biotechnologypharmaceutical research and developmentlaboratory testingdiagnosticspharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapyoncologyhematologyauto-immune disordersinfectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
09/07/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
31/05/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
31/05/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
30/05/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
28/05/2024
EISU
TEAS STATEMENT OF USE RECEIVED
30/04/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/11/2023
EX4G
SOU EXTENSION 4 GRANTED
02/11/2023
EXT4
SOU EXTENSION 4 FILED
02/11/2023
EEXT
SOU TEAS EXTENSION RECEIVED
02/11/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/05/2023
EX3G
SOU EXTENSION 3 GRANTED
01/05/2023
EXT3
SOU EXTENSION 3 FILED
01/05/2023
EEXT
SOU TEAS EXTENSION RECEIVED
01/05/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/11/2022
EX2G
SOU EXTENSION 2 GRANTED
02/11/2022
EXT2
SOU EXTENSION 2 FILED
02/11/2022
EEXT
SOU TEAS EXTENSION RECEIVED
02/11/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/05/2022
EX1G
SOU EXTENSION 1 GRANTED
02/05/2022
EXT1
SOU EXTENSION 1 FILED
02/05/2022
EEXT
SOU TEAS EXTENSION RECEIVED
02/05/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/11/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/09/2021
PUBO
PUBLISHED FOR OPPOSITION
07/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/08/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
28/07/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/07/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
28/07/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/07/2021
DOCK
ASSIGNED TO EXAMINER
20/07/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/04/2021
NWAP
NEW APPLICATION ENTERED
14/01/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN. ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.